EMEA Grants Orphan Drug Status to Active Biotech's Cancer Treatment ANYARA
Active Biotech's ANYARA* project develops a drug for use in cancer targeted therapy, primarily for the treatment of renal cancer. A Phase II/III study is ongoing since the end of 2006. It is a randomized study of ANYARA in combination with interferon-alpha, compared with only interferon-alpha, in patients with advanced renal cancer.
The primary clinical effect parameter for this study is survival and it will include approximately 500 patients at 45 clinics in Europe. Expected survival with conventional treatment for these patients is 10-15 months and the length of the study will depend on the patients' disease progression. An interim analysis based on approximately 200 patients is scheduled for mid-2008.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.